• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Amneal to invest $120M to grow U.S. operations, create 500 jobs

Amneal to invest $120M to grow U.S. operations, create 500 jobs

August 8, 2012
CenterWatch Staff

Amneal Pharmaceuticals, a manufacturer of generic pharmaceuticals based in Hauppauge, N.Y., is investing $120 million in physical plant capital expenditures from 2012-2014 to significantly grow its operations at three of its six current U.S. R&D, manufacturing and distribution facilities.

Planned site expansions and infrastructure enhancement projects will create over 500 new jobs in manufacturing, R&D, distribution and sales at Amneal locations in New York, New Jersey and Kentucky. The facility enlargements and resulting jobs increase will generate an estimated $21 million per year in additional payroll and other benefits to local economies. The company now employs over 1100 people in the United States.

“This major investment in our U.S. operations will more than double Amneal’s production volume and add hundreds of jobs while maintaining our dedication to superior quality in our products as well as throughout our organization," said Chintu Patel, CEO of Amneal. “It enables us to significantly diversify our generics portfolio, further expanding the value we provide our customers.”

Founded in 2002 by brothers Chintu and Chirag Patel, along with their father, Kanu Patel, Amneal has built a diverse portfolio of prescription and over-the-counter drugs across multiple therapeutic areas—pain management, cardiovascular, central nervous system, urology, dermatology, ophthalmic, women’s health and diabetes—in a variety of dosage forms. The capital investment in its manufacturing plants and other facilities will support the firm’s expansion into new products such as high potency medications, controlled substances and softgel capsules; new dosage forms including transdermal patches and injectables; and new therapeutic areas like oncology. Driving further expansion in the U.S. market, Amneal is committed to spending 15%-20% of annual revenue on R&D, while the industry norm is 5%-6%.

“We clearly understand the value of, and are fully committed to, investing and growing within the market we serve, significantly expanding our number of ‘Made in the USA’ products,” said Chirag Patel, president of Amneal. “Generic pharmaceuticals ensure the lowest cost of medications to help make healthcare more affordable to all consumers.”

Last fall the Patels’ accomplishments were recognized with the Ernst & Young 2011 National Entrepreneur of the Year life sciences award.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing